• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过使用低光强率增加莫替沙芬镥-PDT 对肿瘤血管的损伤。

Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

机构信息

Department of Radiation Oncology, School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania 19104, USA.

出版信息

Radiat Res. 2010 Sep;174(3):331-40. doi: 10.1667/RR2075.1.

DOI:10.1667/RR2075.1
PMID:20726728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2995951/
Abstract

Photodynamic therapy (PDT) with low light fluence rate has rarely been studied in protocols that use short drug-light intervals and thus deliver illumination while plasma concentrations of photosensitizer are high, creating a prominent vascular response. In this study, the effects of light fluence rate on PDT response were investigated using motexafin lutetium (10 mg/kg) in combination with 730 nm light and a 180-min drug-light interval. At 180 min, the plasma level of photosensitizer was 5.7 ng/microl compared to 3.1 ng/mg in RIF tumor, and PDT-mediated vascular effects were confirmed by a spasmodic decrease in blood flow during illumination. Light delivery at 25 mW/cm(2) significantly improved long-term tumor responses over that at 75 mW/cm(2). This effect could not be attributed to oxygen conservation at low fluence rate, because 25 mW/cm(2) PDT provided little benefit to tumor hemoglobin oxygen saturation. However, 25 mW/cm(2) PDT did prolong the duration of ischemic insult during illumination and was correspondingly associated with greater decreases in perfusion immediately after PDT, followed by smaller increases in total hemoglobin concentration in the hours after PDT. Increases in blood volume suggest blood pooling from suboptimal vascular damage; thus the smaller increases after 25 mW/cm(2) PDT provide evidence of more widespread vascular damage, which was accompanied by greater decreases in clonogenic survival. Further study of low fluence rate as a means to improve responses to PDT under conditions designed to predominantly damage vasculature is warranted.

摘要

低光强的光动力疗法(PDT)在那些使用短药物-光照间隔的方案中很少被研究,这些方案在光敏剂的血浆浓度高时进行照射,从而产生显著的血管反应。在这项研究中,使用莫替沙芬镥(10mg/kg)联合 730nm 光和 180 分钟的药物-光照间隔,研究了光强对 PDT 反应的影响。在 180 分钟时,与 RIF 肿瘤中的 3.1ng/mg 相比,光敏剂的血浆水平为 5.7ng/µl,并且在光照过程中血流的痉挛性减少证实了 PDT 介导的血管作用。以 25mW/cm2 的光传递显著改善了长期肿瘤反应,优于 75mW/cm2。这种效果不能归因于低光强下的氧气保存,因为 25mW/cm2 的 PDT 对肿瘤血红蛋白氧饱和度几乎没有益处。然而,25mW/cm2 的 PDT 确实延长了光照期间的缺血损伤持续时间,并且相应地与灌注的即刻下降更大相关,随后在 PDT 后几个小时内总血红蛋白浓度的增加较小。血液体积的增加表明从血管损伤不足引起的血液淤积;因此,25mW/cm2 的 PDT 后增加较小,提供了更广泛的血管损伤的证据,这伴随着集落形成存活的更大减少。进一步研究低光强作为一种在主要设计用于损伤血管的条件下改善 PDT 反应的方法是值得的。

相似文献

1
Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.通过使用低光强率增加莫替沙芬镥-PDT 对肿瘤血管的损伤。
Radiat Res. 2010 Sep;174(3):331-40. doi: 10.1667/RR2075.1.
2
Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.氧保护治疗方案的选择决定了肿瘤光动力治疗的炎症反应和疗效。
Cancer Res. 2004 Mar 15;64(6):2120-6. doi: 10.1158/0008-5472.can-03-3513.
3
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.镥莫替沙芬介导的间质光动力疗法用于局部复发性前列腺癌患者的I期试验的更新结果。
J Environ Pathol Toxicol Oncol. 2006;25(1-2):373-87. doi: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.230.
4
Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.用莫替沙芬镥进行光动力疗法治疗直肠癌:犬的临床前模型
J Surg Res. 2006 Oct;135(2):323-30. doi: 10.1016/j.jss.2006.01.020. Epub 2006 May 2.
5
Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.恶性间皮瘤的光动力疗法:优化治疗方案的临床前研究
Photochem Photobiol. 2001 Apr;73(4):410-7. doi: 10.1562/0031-8655(2001)073<0410:ptfmmp>2.0.co;2.
6
In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.用于莫替沙芬镥介导的复发性乳腺癌光动力疗法的体内光剂量测定
Lasers Surg Med. 2002;31(5):305-12. doi: 10.1002/lsm.10115.
7
Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.基于Foscan的体内光动力治疗:肿瘤、血浆和白细胞中疗效与Foscan蓄积之间的相关性。
Oncol Rep. 2004 Sep;12(3):639-45.
8
Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.利用漫射光对人类前列腺光动力疗法进行实时原位监测。
Photochem Photobiol. 2006 Sep-Oct;82(5):1279-84. doi: 10.1562/2005-10-19-RA-721.
9
Reactive oxygen species explicit dosimetry to predict tumor growth for benzoporphyrin derivative-mediated vascular photodynamic therapy.活性氧种显式剂量测定预测苯并卟啉衍生物介导的血管光动力疗法的肿瘤生长。
J Biomed Opt. 2020 Jan;25(6):1-13. doi: 10.1117/1.JBO.25.6.063805.
10
Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.莫替沙芬镥光动力疗法诱导血管细胞发生氧化还原敏感型凋亡。
Arterioscler Thromb Vasc Biol. 2001 May;21(5):759-64. doi: 10.1161/01.atv.21.5.759.

引用本文的文献

1
Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.手术炎症改变了对术中光动力疗法的免疫反应。
Cancer Res Commun. 2023 Sep 11;3(9):1810-1822. doi: 10.1158/2767-9764.CRC-22-0494. eCollection 2023 Sep.
2
Photodynamic therapy induced cell cycle arrest and cancer cell synchronization: review.光动力疗法诱导细胞周期停滞与癌细胞同步化:综述
Front Oncol. 2023 Jul 12;13:1225694. doi: 10.3389/fonc.2023.1225694. eCollection 2023.
3
Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy.

本文引用的文献

1
Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.光动力疗法中血啉单甲醚光动力治疗的生理和细胞毒性反应的肿瘤内异质性与通量率相关。
Photochem Photobiol Sci. 2009 Dec;8(12):1683-93. doi: 10.1039/b9pp00004f. Epub 2009 Oct 15.
2
Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model.在体外放射治疗前对博来霉素进行光化学内化可改善人肉瘤模型中的局部区域控制。
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):878-85. doi: 10.1016/j.ijrobp.2009.04.039. Epub 2009 Aug 6.
3
Interstitial Doppler optical coherence tomography as a local tumor necrosis predictor in photodynamic therapy of prostatic carcinoma: an in vivo study.
血流测量有助于优化个性化光动力疗法的光输送。
Cancers (Basel). 2020 Jun 15;12(6):1584. doi: 10.3390/cancers12061584.
4
Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy.同步递送氧和光敏剂以缓解缺氧肿瘤微环境并显著增强光动力疗法。
Drug Deliv. 2018 Nov;25(1):585-599. doi: 10.1080/10717544.2018.1435751.
5
Early assessment of tumor response to photodynamic therapy using combined diffuse optical and diffuse correlation spectroscopy to predict treatment outcome.利用漫射光学和漫射相关光谱联用技术对肿瘤光动力治疗反应进行早期评估以预测治疗结果。
Oncotarget. 2017 Mar 21;8(12):19902-19913. doi: 10.18632/oncotarget.15720.
6
Evaluation of the 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide (HPPH) mediated photodynamic therapy by macroscopic singlet oxygen modeling.通过宏观单线态氧模型评估2-(1-己氧基乙基)-2-脱乙烯基焦脱镁叶绿酸(HPPH)介导的光动力疗法。
J Biophotonics. 2016 Dec;9(11-12):1344-1354. doi: 10.1002/jbio.201600121. Epub 2016 Sep 22.
7
Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma.口腔浅表鳞状细胞癌光动力治疗反应的术中光学评估
J Biomed Opt. 2016 Jan;21(1):18002. doi: 10.1117/1.JBO.21.1.018002.
8
Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy.全氟碳纳米颗粒可提高光动力疗法中的活性氧水平并抑制肿瘤生长。
Nat Commun. 2015 Nov 3;6:8785. doi: 10.1038/ncomms9785.
9
Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.光动力疗法诱导的血管生成信号:改善治疗反应的后果及解决方案
Isr J Chem. 2012 Sep 1;52(8-9):681-690. doi: 10.1002/ijch.201200011.
10
Folic acid conjugated ferritins as photosensitizer carriers for photodynamic therapy.叶酸共轭铁蛋白作为用于光动力疗法的光敏剂载体
Nanoscale. 2015 Jun 21;7(23):10330-3. doi: 10.1039/c5nr01833a.
间质多普勒光学相干断层扫描作为前列腺癌光动力治疗中局部肿瘤坏死的预测指标:一项体内研究
Cancer Res. 2008 Dec 1;68(23):9987-95. doi: 10.1158/0008-5472.CAN-08-1128.
4
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.莫替沙芬镥光动力疗法治疗前列腺癌:对前列腺特异性抗原的短期和长期影响
Clin Cancer Res. 2008 Aug 1;14(15):4869-76. doi: 10.1158/1078-0432.CCR-08-0317.
5
Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy.低能量率临床光动力治疗后针对血管肉瘤的免疫反应。
J Environ Pathol Toxicol Oncol. 2008;27(1):35-42. doi: 10.1615/jenvironpatholtoxicoloncol.v27.i1.40.
6
Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy.在维替泊芬介导的血管靶向治疗中,前列腺肿瘤内部与外周血管系统之间的差异。
Int J Cancer. 2008 Aug 1;123(3):695-701. doi: 10.1002/ijc.23538.
7
Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.长时间的光传递可提高光动力疗法的疗效。
Clin Cancer Res. 2008 May 1;14(9):2796-805. doi: 10.1158/1078-0432.CCR-07-4705.
8
Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy.光动力血管靶向治疗后血管灌注和大分子外渗的活体显微镜分析。
Pharm Res. 2008 Aug;25(8):1873-80. doi: 10.1007/s11095-008-9604-5. Epub 2008 Apr 30.
9
Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.光敏剂剂量对光动力疗法中fluence率反应的影响。 (注:fluence rate可能是“光通量率”等专业术语,这里直接保留英文未翻译,因为不太明确在该语境下准确的中文表述)
Photochem Photobiol. 2007 Sep-Oct;83(5):1040-8. doi: 10.1111/j.1751-1097.2007.00139.x.
10
The potential application of chlorin e6-polyvinylpyrrolidone formulation in photodynamic therapy.二氢卟吩e6-聚乙烯吡咯烷酮制剂在光动力疗法中的潜在应用。
Photochem Photobiol Sci. 2006 Nov;5(11):1031-7. doi: 10.1039/b605772a. Epub 2006 Sep 21.